Actionable news
All posts from Actionable news
Actionable news in DVAX: Dynavax Technologies Corporation,

Dynavax Presents Encouraging Data From Clinical Trial of Immuno-Oncology Product Candidate, SD-101

BERKELEY, CA, Apr 18, 2016 (Marketwired via COMTEX) -- Dynavax Technologies Corporation DVAX, +4.58% today announced encouraging additional data from Part 1 of a Phase 1/2 study (LYM-01) evaluating the company's lead immunotherapy product candidate, SD-101, in combination with low-dose radiation in lymphoma patients. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana.

Clinical Findings Included:

--  SD-101 was reported to be well tolerated across all dose cohorts with no
    dose limiting toxicities.
--  The combination of direct injection of SD-101 into a tumor and low-dose
    radiation resulted in changes in the tumor microenvironment that
    potentially induced a systemic anti-tumor response.
--  Tumors not directly injected with SD-101 also decreased in volume across
    all dose groups, and in most patients, remained stable for at least 180
    to 360 days.
--  No evidence of a dose response was observed, although limited numbers of
    patients were examined.

"This clinical trial design is unique and takes advantage of the fact that lymphoma patients have easily injectable sites of disease. The local injections are conveniently added to low dose radiotherapy, a standard treatment for low grade lymphoma," stated Ronald Levy, M.D., professor and chief of the Division of Oncology at Stanford School of Medicine and the study's lead clinical investigator. "We are pleased to have already demonstrated a safety profile, pharmacodynamics and preliminary efficacy in this study," he said.

"These additional data bolster the findings that were presented at the American Society of Hematology conference in December, demonstrating SD-101's ability to...